Protalix BioTherapeutics to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York City

Protalix BioTherapeutics to Present at the Oppenheimer 23rd Annual Healthcare
Conference in New York City

CARMIEL, Israel, Dec. 5, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,
Inc. (NYSE-MKT:PLX) (TASE:PLX), today announced that Yossi Maimon, the
Company's Vice President and Chief Financial Officer, will present at the
Oppenheimer 23rd Annual Healthcare Conference on Wednesday, December 12, 2012
at 11:10AM EST. The conference will be held at The Waldorf-Astoria Hotel in
New York City on December 12-13, 2012.

A live webcast of the presentation will be available at www.protalix.com on
the event calendar page. A replay will be archived and available after the
conclusion of the presentation for 30 days.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins expressed through its
proprietary plant cell based expression system, ProCellEx®. Protalix's unique
expression system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner. Protalix's first
approved product manufactured by ProCellEx, ELELYSO™ (taliglucerase alfa), an
enzyme replacement therapy for the treatment of Gaucher disease, was approved
for marketing by the U.S. Food and Drug Administration in May 2012, and by
Israel's Ministry of Health in September 2012. Additional marketing
applications for taliglucerase alfa have been filed in other countries.
Protalix is partnered with Pfizer Inc. for worldwide development and
commercialization, excluding Israel, where Protalix retains full rights.
Protalix's development pipeline also includes the following product
candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A
protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant
human acetylcholinesterase in development for several therapeutic and
prophylactic indications, a biodefense program and an organophosphate-based
pesticide treatment program; an orally-delivered glucocerebrosidase enzyme
that is naturally encased in carrot cells, also for the treatment of Gaucher
disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel®) for
the treatment of certain immune diseases such as rheumatoid arthritis,
juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and
plaque psoriasis; and others.

CONTACT: Investor Contact
         Tricia Swanson
         The Trout Group, LLC
         +1 646 378 2953
         tswanson@troutgroup.com

         Media Contact
         Kari Watson
         MacDougall Biomedical Communications
         + 1 781-235-3060
         kwatson@macbiocom.com